Antithrombin Market - Regional
Analysis
On the basis of region, the
global Antithrombin
Market is segmented into North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. North America is expected to gain significant
traction in the global antithrombin market, followed by Europe, owing to
adoption of robust developed technologies and antithrombin therapies, and high
awareness and increasing regulatory approval of drugs in these regions.
Antithrombin is a protein present
in blood that inhibits blood clotting by inactivating thrombin. Antithrombin is
produced by liver and consists of 432 amino acids. There are two major reasons
of antithrombin deficiency, which include acquired antithrombin deficiency
caused due to other diseases such as nephrotic syndrome, liver failure, severe
trauma, and metastatic tumors and inherited antithrombin deficiency caused due
to a genetic mutation or abnormality. According to the NCBI (National Center
for Biotechnology Information), inherited antithrombin deficiency is a rarely
occurring deficiency and only a maximum of 0.2% of the global population has
this deficiency. One of the most popular drugs for the treatment of
antithrombin deficiency available in the market is ATryn, which was developed
by rEVO Biologics and received the U.S. Food and Drug Administration (FDA)
approval in 2009. Antithrombin shows synergistic activity with heparin that
enhances the antithrombin binding with Thrombin (factor II a) and Factor Xa.
Antithrombin III blood test is required to measure the amount of deficiency of
antithrombin that is causing the blood to clot more easily than normal.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2018
Antithrombin Market – Market
Dynamics
Increasing incidence of
coagulation disorders, open heart surgeries, and extracorporeal circulation
during hemodialysis is augmenting growth of antithrombin market. According to
the Centers for Disease Control and Prevention (CDC), 2015, around 900,000 people
is affected from venous thromboembolism every year in the U.S. Furthermore, 5
to 8% of the U.S. population has increased risk of suffering from thrombosis
due to one of the several genetic risk factors known as inherited
thrombophilia.
Therapeutic drug pipeline or
advancements in drug administering technology is also expected to fuel growth
of antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam
Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi
therapeutic targeting antithrombin (AT). This therapeutic that can be used for
the treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage
(Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s product
called as ATryn Antithrombin (Recombinant), derived from human blood donors, is
used for hereditary antithrombin deficiency and it recently got market approval
in the U.S., thereby significantly contributing to the growth of antithrombin
market. Therefore, introduction of new types of antithrombin products with
different indication over the forecast period is expected to fuel growth of the
global antithrombin market. Furthermore, increasing use of antithrombin in
combination with heparin is likely to support the growth of antithrombin
market. For instance, heparin resistance in cardiac surgery is likely to create
opportunities for use of antithrombin products in anticoagulation therapy.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/antithrombin-market-2018
However, increasing regulations
on animal testing have impeded a number of healthcare companies from
manufacturing new drugs, thereby restraining the market growth.
Moreover, improving healthcare
infrastructure in emerging economies such as China and India, and increasing
research and development activities are contributing towards the growth of
antithrombin market in Asia Pacific region. For instance, in 2016, China
Biologic Products, Inc.’s subsidiary, Shandong Taibang Biological Products Co.
Ltd., recently obtained approval from the China Food and Drug Administration
(CFDA) to begin human clinical trials using its Human Antithrombin III (ATIII)
product for the treatment of hereditary and acquired ATIII deficiency which are
more prone during surgical or obstetrical procedures, and treatment of
thromboembolism.
Antithrombin Market – Competitive
Landscape
The antithrombin market is
characterized by the presence of few established players. There is stiff
competition in the market, as these few players occupy major market share. Key
players operating in the global antithrombin market include Grifols, Shire
Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, Scripps
Laboratories Inc., GTC Biotherapeutics, Inc.’s, Green Cross Corp., and BDI
Pharma.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2018
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment